April 24, 2019 10:30 AM EDT

MD Anderson tries to assure researchers in town hall meeting that Asian ‘ethnicity’ is not the driving force behind purge

Amber Tong

Should Chinese researchers at the MD Anderson Cancer Center be worried in the wake of three Asian scientists’ dismissals tied to alleged foreign influence?

The answer is a firm no, according to administrators who hosted a town hall on Tuesday for alarmed employees. Science, which first broke the news about the firings together with the Houston Chronicle, obtained an recording recording from the meeting.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

MD Anderson tries to assure researchers in town hall meeting that Asian ‘ethnicity’ is not the driving force behind purge

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

MD An­der­son tries to as­sure re­searchers in town hall meet­ing that Asian ‘eth­nic­i­ty’ is not the dri­ving force be­hind purge

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

MD Anderson tries to assure researchers in town hall meeting that Asian ‘ethnicity’ is not the driving force behind purge

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Updated: Roche buys out CAR-T partner Poseida for $1B upfront